140 related articles for article (PubMed ID: 31306338)
1. The Successful Sequential Use of Plerixafor and Eltrombopag For Hematopoietic Cell Transplantation in a Child With High-risk Neuroblastoma.
Marjanska A; Czyzewski K; Debski R; Krenska A; Wysocki M; Styczynski J
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e680-e682. PubMed ID: 31306338
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag use in a patient with Wiskott-Aldrich syndrome.
Gabelli M; Marzollo A; Notarangelo LD; Basso G; Putti MC
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643468
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag.
Tang C; Chen F; Kong D; Ma Q; Dai H; Yin J; Li Z; Chen J; Zhu X; Mao X; Wu D; Tang X
J Hematol Oncol; 2018 Aug; 11(1):103. PubMed ID: 30115080
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation.
Fu H; Zhang X; Han T; Mo X; Wang Y; Chen H; Han W; Wang J; Wang F; Yan C; Zhang Y; Sun Y; Liu K; Huang X; Xu L
Bone Marrow Transplant; 2019 Aug; 54(8):1310-1318. PubMed ID: 30664724
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
[TBL] [Abstract][Full Text] [Related]
6. Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children.
Uria-Oficialdegui ML; Alonso L; Benitez-Carabante MI; Renedo B; Oliveras M; Diaz-de-Heredia C
Pediatr Transplant; 2021 Jun; 25(4):e14010. PubMed ID: 33742757
[TBL] [Abstract][Full Text] [Related]
7. Successful Use of Eltrombopag in a Child With Hurler Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation.
Naithani R; Sachdev M; Uttam R
J Pediatr Hematol Oncol; 2016 Mar; 38(2):163-4. PubMed ID: 26491856
[No Abstract] [Full Text] [Related]
8. Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia.
Kanno M; Onoda T; Meguro T; Sato H; Mitsui T
Pediatr Int; 2018 Feb; 60(2):191-192. PubMed ID: 29271533
[No Abstract] [Full Text] [Related]
9. [Successful treatment of post-allogeneic hematopoietic transplant immune thrombocytopenia with eltrombopag].
Narita Y; Uchiyama T; Mizumoto C; Takeoka T; Tomo K; Tsuji M; Ohno T
Rinsho Ketsueki; 2018; 59(11):2418-2422. PubMed ID: 30531136
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag Therapy in Children With Rare Disorders Associated With Thrombocytopenia.
Frączkiewicz J; Sęga-Pondel D; Kazanowska B; Ussowicz M
J Pediatr Hematol Oncol; 2020 Mar; 42(2):113-117. PubMed ID: 31205222
[TBL] [Abstract][Full Text] [Related]
11. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma.
Modak S; Cheung IY; Kushner BH; Kramer K; Reich L; Cheung NK
Pediatr Blood Cancer; 2012 Mar; 58(3):469-71. PubMed ID: 21416584
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
Modi Y; Shaaban H; Gauchan D; Maroules M
J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
[TBL] [Abstract][Full Text] [Related]
14. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
[No Abstract] [Full Text] [Related]
15. Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation;
Kosmas C; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Grivas A; Athanasopoulos A; Lianos E
Leuk Lymphoma; 2019 Jul; 60(7):1819-1822. PubMed ID: 30618317
[No Abstract] [Full Text] [Related]
16. Eltrombopag for post-transplant cytopenias due to poor graft function.
Marotta S; Marano L; Ricci P; Cacace F; Frieri C; Simeone L; Trastulli F; Vitiello S; Cardano F; Pane F; Risitano AM
Bone Marrow Transplant; 2019 Aug; 54(8):1346-1353. PubMed ID: 30679824
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study.
Giammarco S; Sica S; Chiusolo P; Laurenti L; Sorá F; Martino M; Metafuni E; Busca A; Risitano A; Vallejo C; Bacigalupo A
Int J Hematol; 2021 Aug; 114(2):228-234. PubMed ID: 33886103
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
19. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation.
Busca A; Dellacasa C; Giaccone L; Manetta S; Biale L; Godio L; Aydin S; Festuccia M; Brunello L; Bruno B
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1765-1770. PubMed ID: 29684566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
